Education
About Us
Working with TipRanks
Follow Us
Claude Nicaise Insider Profile
4 Followers
Claude Nicaise, Director at Sarepta Therapeutics, holds 27.81K shares in Sarepta Therapeutics (Ticker: SRPT), holds ― shares in Chemomab Therapeutics (Ticker: CMMB), holds ― shares in Gain Therapeutics (Ticker: GANX).
Claude Nicaise has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Claude Nicaise holds in companies
Most Profitable Insider Trade
The most profitable trade made by Claude Nicaise
Claude Nicaise's Trading History
Sarepta Therapeutics
Mar 13, 2025
Director
Uninformative Buy
245.40K
$606.58K
Chemomab Therapeutics
―
Director
―
―
Gain Therapeutics
―
Director
―
―
Cassava Sciences
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Claude Nicaise's performance on stock
You May Also Like
Claude Nicaise insider profile FAQ
What is the percentage of profitable transactions made by Claude Nicaise?
The percentage of profitable transactions made by Claude Nicaise is ―.
What is the average return per transaction made by Claude Nicaise?
The average return per transaction made by Claude Nicaise is ―.
What stocks does Claude Nicaise hold?
Claude Nicaise holds: SRPT, CMMB, GANX, SAVA stocks.
What was Claude Nicaise’s latest transaction?
Claude Nicaise latest transaction was an Uninformative Buy of $245.40K.
What was Claude Nicaise's most profitable transaction?
Claude Nicaise’s most profitable transaction was an Informative Sell of SRPT stock on March 13, 2025. The return on the trade was 81.40%.
What is Claude Nicaise's role in Sarepta Therapeutics?
Claude Nicaise's role in Sarepta Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.